Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 6,101 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $91.23, for a total transaction of $556,594.23. Following the completion of the sale, the director directly owned 685,501 shares in the company, valued at approximately $62,538,256.23. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Stock Up 2.1%

Shares of KYMR stock traded up $1.87 during trading on Friday, hitting $89.68. The company had a trading volume of 1,863,753 shares, compared to its average volume of 801,466. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28. The stock’s 50-day moving average is $64.14 and its two-hundred day moving average is $51.43.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KYMR. Wellington Management Group LLP lifted its holdings in Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock worth $164,134,000 after buying an additional 689,547 shares during the period. BVF Inc. IL grew its position in shares of Kymera Therapeutics by 6.6% in the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after buying an additional 340,909 shares during the period. Vanguard Group Inc. grew its holdings in Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after purchasing an additional 344,080 shares during the period. Siren L.L.C. boosted its position in shares of Kymera Therapeutics by 9.1% in the 1st quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock worth $88,687,000 after purchasing an additional 270,580 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Kymera Therapeutics by 5.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after purchasing an additional 59,347 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KYMR. UBS Group upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Citigroup lifted their target price on shares of Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday. B. Riley boosted their price target on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. JPMorgan Chase & Co. raised their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, BTIG Research set a $138.00 target price on Kymera Therapeutics in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $112.80.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.